BIOVF - Swedish Orphan Biovitrum AB (publ) (BIOVF) Q4 2023 Earnings Call Transcript
2024-02-08 14:21:03 ET
Swedish Orphan Biovitrum AB (publ) (BIOVF)
Q4 2023 Results Conference Call
February 08, 2024 08:00 AM ET
Company Participants
Guido Oelkers - Chief Executive Officer
Henrik Stenqvist - Chief Financial Officer
Lydia Abad-Franch - Head of R&D and Chief Medical Officer
Armin Reininger - Senior Certificate Advisor
Conference Call Participants
Eun Yang - Jefferies LLC
Charles Mabbutt - Morgan Stanley
Niall Alexander - Deutsche Bank
Alistair Campbell - RBC Capital Markets
Christopher Uhde - Uhde SEB
Yifeng Liu - HSBC
Viktor Sundberg - Nordea Markets
Erik Hultgard - Carnegie Investment Bank AB
Presentation
Operator
Ladies and gentlemen, welcome to the Q4 2023 Report Conference Call and Live Webcast. I am Sandra, the Chorus Call Operator. I would like to remind you that all participants are in a listen-only mode and the conference is being recorded. [Operator Instructions]
At this time, it is my pleasure to hand over to Guido Oelkers, CEO. Please go ahead, sir.
Guido Oelkers
Yes, thank you so much and hello everyone. This is Guido, CEO of Sobi. We are delighted to welcome you into the fourth quarter and full-year 2023 conference call for investors and analysts. Overall, we can say that we are pleased with our performance in 2023 and the year has exceeded our expectations. We posted this presentation to sobi.com earlier today.
Let’s go to Slide #2. We would like to remind you as per usual of the forward looking statement and unless stated otherwise, we liked making comments that most related to the fourth quarter full-year performance in 2023 at constant exchange rate in million Swedish kroner.
With that please turn to Slide #3. Today we plan to cover key aspects of our Q4 and full-year report. I’m joined by Henrik Stenqvist, our CFO and Lydia Abad-Franch, Head of R&D and Chief Medical Officer and during the Q&A session by Armin Reininger, our Senior Certificate Advisor.
We plan to review the presentation first and then have Q&A until around 2:00PM Swedish time. For those on the phone, please join in the queue of this questions by pressing star one, we propose you ask only one question, maximum two at a time.
Please turn to Slide #4. As said, we are pleased with the 2023 performance, which has been driven successfully executing on our strategy throughout the year. 15% growth in Q4 and 12% growth for the full-year make us one of the fastest growing company in the rare disease space and it is around two times faster than the expected growth for the rare disease market globally....
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q4 2023 Earnings Call Transcript